JP2016503803A5 - - Google Patents

Download PDF

Info

Publication number
JP2016503803A5
JP2016503803A5 JP2015549792A JP2015549792A JP2016503803A5 JP 2016503803 A5 JP2016503803 A5 JP 2016503803A5 JP 2015549792 A JP2015549792 A JP 2015549792A JP 2015549792 A JP2015549792 A JP 2015549792A JP 2016503803 A5 JP2016503803 A5 JP 2016503803A5
Authority
JP
Japan
Prior art keywords
weight percent
amount
glatiramer acetate
oral tablet
hydroxypropylcellulose
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2015549792A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016503803A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2013/077034 external-priority patent/WO2014100639A1/en
Publication of JP2016503803A publication Critical patent/JP2016503803A/ja
Publication of JP2016503803A5 publication Critical patent/JP2016503803A5/ja
Withdrawn legal-status Critical Current

Links

JP2015549792A 2012-12-21 2013-12-20 酢酸グラチラマーの経粘膜送達 Withdrawn JP2016503803A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261745226P 2012-12-21 2012-12-21
US61/745,226 2012-12-21
PCT/US2013/077034 WO2014100639A1 (en) 2012-12-21 2013-12-20 Transmucosal delivery of glatiramer acetate

Publications (2)

Publication Number Publication Date
JP2016503803A JP2016503803A (ja) 2016-02-08
JP2016503803A5 true JP2016503803A5 (enExample) 2017-02-02

Family

ID=50979257

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015549792A Withdrawn JP2016503803A (ja) 2012-12-21 2013-12-20 酢酸グラチラマーの経粘膜送達

Country Status (15)

Country Link
US (1) US20160193276A1 (enExample)
EP (1) EP2934492A4 (enExample)
JP (1) JP2016503803A (enExample)
KR (1) KR20150111918A (enExample)
CN (1) CN104869983A (enExample)
AU (1) AU2013361053A1 (enExample)
BR (1) BR112015014095A2 (enExample)
CA (1) CA2895359A1 (enExample)
EA (1) EA201591188A1 (enExample)
HK (2) HK1214134A1 (enExample)
IL (1) IL239280A0 (enExample)
MX (1) MX2015007678A (enExample)
SG (1) SG11201504422XA (enExample)
WO (1) WO2014100639A1 (enExample)
ZA (1) ZA201505049B (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2602977T3 (es) 2010-10-11 2017-02-23 Teva Pharmaceutical Industries Ltd. Biomarcadores de citocinas como biomarcadores predictivos de la respuesta clínica para acetato de glatirámero
AU2012323345A1 (en) 2011-10-10 2014-05-22 Teva Pharmaceutical Industries Ltd. Single nucleotide polymorphisms useful to predict clinical response for glatiramer acetate
UY35790A (es) 2013-10-21 2015-05-29 Teva Pharma Marcadores genéticos que predicen la respuesta al acetato de glatiramer
US10493122B2 (en) * 2014-03-17 2019-12-03 Mapi Pharma Ltd. Sublingual delivery of glatiramer acetate
CN106924175B (zh) * 2015-12-29 2020-07-03 深圳翰宇药业股份有限公司 一种治疗多发性硬化症的药物组合物
CN108601737A (zh) * 2016-02-12 2018-09-28 特华制药株式会社 干法制粒物和含有该干法制粒物的固态制剂及它的制造方法
WO2019002228A1 (en) 2017-06-26 2019-01-03 Institut Pasteur TREATMENTS TO REMOVE HIV RESERVOIRS AND REDUCE VIRAL LOAD

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003522799A (ja) * 2000-02-18 2003-07-29 イエダ・リサーチ・アンド・ディベロップメント・カンパニー・リミテッド・アット・ザ・ウェイズマン・インスティテュート・オブ・サイエンス コポリマー1の経口、経鼻および経肺投与製剤
ZA200206457B (en) * 2000-02-18 2003-08-13 Yeda Res & Dev Oral, nasal and pulmonary dosage formulations of copolymer 1.
AU2002320360B2 (en) * 2001-07-10 2005-05-26 Teva Pharmaceutical Industries Ltd. Drug delivery system for zero order, zero order-biphasic, ascending or descending drug delivery
HRP20130622T1 (en) * 2005-02-17 2013-08-31 Teva Pharmaceutical Industries Ltd. Combination therapy with glatiramer acetate and rasagiline for the treatment of multiple sclerosis
CA2623018A1 (en) * 2005-11-22 2007-05-31 Teva Pharmaceutical Industries Ltd. Pharmaceutical compositions of telmisartan
EP1978939A2 (en) * 2005-12-27 2008-10-15 Jubilant Organosys Limited Mouth dissolving pharmaceutical composition and process for preparing the same using a high amount of silicon dioxine
PL2526933T3 (pl) * 2006-09-22 2015-08-31 Pharmacyclics Llc Inhibitory kinazy tyrozynowej Brutona
ES2329327B1 (es) * 2008-03-19 2010-09-17 Proyecto De Biomedicina Cima, S.L. Combinaciones sinergicas de 5'-metiltioadenosina.

Similar Documents

Publication Publication Date Title
CA2251886C (en) An oral pharmaceutical formulation containing ibandronate
US10258575B2 (en) Oral drug dosage forms having desired drug release profiles and uses thereof
JP2018517715A5 (enExample)
JP2006505566A5 (enExample)
JP2016516698A5 (enExample)
JP2011509295A5 (enExample)
JP2016522191A (ja) ロスバスタチンまたはその薬学的に許容可能な塩を含有する膜コーティング層を含む複合製剤
JP2014221827A5 (enExample)
JP2018521985A5 (enExample)
SI3106148T1 (en) ORODISPERSIBILITY DOSING UNIT, CONTAINING ESTETROL COMPONENT
JP5810819B2 (ja) 積層錠
SI2760821T1 (en) A salt salt of an anti-inflammatory substituted cyclobutenedione compound
TWI480067B (zh) 經包衣之固體製劑
ES2781110T3 (es) Preparación de material compuesto que comprende una capa de recubrimiento de película, que contiene un inhibidor de la 5-alfa-reductasa, y método para la producción de la preparación de material compuesto
JP5517327B2 (ja) 口腔内崩壊錠用組成物
JP2018118966A5 (enExample)
JP2018039810A5 (enExample)
RU2018137590A (ru) Фармацевтические композиции для производного n-пропаргиламина
CA2648538A1 (en) Oral rapid release pharmaceutical formulation for pyridylmethylsulfinyl-benzimidazoles
CN102958522B (zh) 微粒包衣制剂
JPH05246845A (ja) イブプロフェン含有解熱鎮痛剤
JP2015521647A5 (enExample)
JP2015129124A (ja) ミルタザピンを含有する口腔内崩壊錠
WO2015008825A1 (ja) 口腔内崩壊錠
JP2017511350A5 (enExample)